Literature DB >> 11138781

The strategy of blocking the chemokine system to combat disease.

A E Proudfoot1, C A Power, T N Wells.   

Abstract

One of the key characteristics of inflammation is the recruitment of leukocytes to the site of inflammation. Most anti-inflammatory strategies act intracellularly on the target cells, but after the cells have migrated to the site. We therefore propose that the prevention of cellular recruitment by blockade of the relevant chemokine receptor/ligand pair would present a novel therapy in that it would act upstream of the therapies currently in use. The chemokine system is a complex family of over 40 ligands and 18 receptors and as such may appear difficult to inhibit selectively. In the first part of the article we discuss the specificity mechanisms that are beginning to be unraveled which we believe occur at multiple levels. These levels of control of specificity include the temporal regulation of both the ligands and their receptors, which are under the control of pro-inflammatory cytokines; the localization of chemokines on cell surfaces through their interactions with glycosaminoglycans; differential receptor/ligand interactions; and different patterns of receptor trafficking, to name but a few. The chemokine system has been validated as providing good therapeutic targets by several approaches. In our laboratory, we have used a chemokine receptor antagonist in models of inflammation in vivo to demonstrate that this approach is successful in reducing inflammation. Chemokine receptors belong to the class of seven transmembrane spanning receptors, which have proven to be excellent targets by the pharmaceutical industry for many diseases. The number of small molecule inhibitors of chemokine receptors is rapidly growing in the patent literature, and reports both in the literature as well as conferences in the field have shown them to be effective in inflammatory disease models, as well as inhibiting HIV-1 infection. Since clinical trials will begin this year with some of these molecules, hopefully we will fairly soon have the answer of the efficacy of this therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11138781     DOI: 10.1034/j.1600-065x.2000.17721.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  17 in total

1.  Coevolutionary patterns in plasminogen activation.

Authors:  Inna P Gladysheva; Ryan B Turner; Irina Y Sazonova; Lin Liu; Guy L Reed
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-23       Impact factor: 11.205

Review 2.  [Chemokine--possible new options for the treatment of multiple sclerosis].

Authors:  C Trebst; R M Ransohoff; A Windhagen; M Stangel
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

3.  The role of Ifng in alterations in liver gene expression in a mouse model of fulminant autoimmune hepatitis.

Authors:  Michael W Milks; James G Cripps; Heping Lin; Jing Wang; Richard T Robinson; Jennifer L Sargent; Michael L Whitfield; James D Gorham
Journal:  Liver Int       Date:  2009-04-16       Impact factor: 5.828

4.  Ticks from diverse genera encode chemokine-inhibitory evasin proteins.

Authors:  Jenni Hayward; Julie Sanchez; Andrew Perry; Cheng Huang; Manuel Rodriguez Valle; Meritxell Canals; Richard J Payne; Martin J Stone
Journal:  J Biol Chem       Date:  2017-08-04       Impact factor: 5.157

Review 5.  Chemoattractant receptor signaling and the control of lymphocyte migration.

Authors:  John H Kehrl
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

6.  The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis.

Authors:  Amel Meraouna; Geraldine Cizeron-Clairac; Rozen Le Panse; Jacky Bismuth; Frederique Truffault; Chantal Tallaksen; Sonia Berrih-Aknin
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

7.  Regulation of CCR5 expression and MIP-1alpha production in CD4+ T cells from patients with rheumatoid arthritis.

Authors:  C R Wang; M F Liu
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

Review 8.  Novel biological strategies for treatment of wear particle-induced periprosthetic osteolysis of orthopaedic implants for joint replacement.

Authors:  S B Goodman; E Gibon; J Pajarinen; T-H Lin; M Keeney; P-G Ren; C Nich; Z Yao; K Egashira; F Yang; Y T Konttinen
Journal:  J R Soc Interface       Date:  2014-01-29       Impact factor: 4.118

9.  Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension.

Authors:  Ahmed A Elmarakby; Jeffrey E Quigley; Jeffrey J Olearczyk; Aarthi Sridhar; Anthony K Cook; Edward W Inscho; David M Pollock; John D Imig
Journal:  Hypertension       Date:  2007-10-15       Impact factor: 10.190

Review 10.  Response of chemokine antagonists to inflammation in injured spinal cord.

Authors:  Lawrence F Eng; Yuen Ling Lee
Journal:  Neurochem Res       Date:  2003-01       Impact factor: 4.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.